Interesting statement in the conclusion made, I know we have talked about this being the case, but to see it in the article is good to see.
"None of the products from different manufactures analyzed fulfills any characteristics or requirements to be classified as a generic product of another manufacture, but each of which presents a new medical entity in a regulatory sense unless its similarity can be convincingly demonstrated by further investigations."
research reports and media, page-3857
-
- There are more pages in this discussion • 572 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
26.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $91.06M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 28200 | 35.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 66697 | 1 |
View Market Depth
| Last trade - 10.06am 18/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |
Day chart unavailable